|
|
TCRT-PGEN Fundamental & Technical Discussion Board
|
|
||
Treating Cancer with Genetically Engineered T Cellsthis is another paper from dr Rosenberg's group that has a neat figure 3 where you can see the removal of a metastatic melanoma mass from the pelvic region of a patient who was at that time in 2011 in remission for 4 years so she would have been from one of the experiments in an earlier paper i have posted here from the 2006-07 time period. but they note here that several of these cases are the first patients with complete remissions from this early TCR work for his group. two separate first survivors from early TCR work. it really is too bad that people here like clsm and vorlon who seem to have an interest do not study this stuff enuff to understand why the vaccines therapies are limited and why just 'exploding' a tumor cell can lead to the type of complete remission that follows from a neoantigen specific TCR can bring. i cannot do anything about it since it is impossible to explain this field to people on a bulletin board, it really requires reading the work and making the effort to understand the science that underlies this therapeutic technique and how dr Rosenberg got to the point where he could find the 'reactive' T cell and determine the coding for the alpha and beta chains of the TCR that cell has coded for. anyway,i really do feel like we are on the side of god here, i have not found any other researcher wh can match the work of dr Rosenberg in the depth and breadth of his knowledge and understanding. it is easy to see why people are inspired to work for him and produce this tremendous volume of work that has already saved the lives of so many of his experimental patients. the lucky ones. he talks about some of the problems that have come up as the wor evolved, patients who died because of unexpected autoimmune reactions or on target off tumor attacks. Treating Cancer with Genetically Engineered T CellsCancer regression using TCR gene-modified T cells. Shown is an X-ray computed tomography (CT) scan of the abdomen of a patient with metastatic melanoma before and >2 years after administration of anti-gp100 TCR gene transduced autologous T cells16. The dashed circle indicates the position of one of the patients’ metastatic tumors in a pelvic lymph node. The long line-like element in the pre-treatment image is a biopsy needle. The patient continues to be disease free four years post-treatment. |
return to message board, top of board |